Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma).
Andecaliximab Biosimilar Antibody
$205.00 – $2,500.00
Andecaliximab is a humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against human matrix metallopeptidase 9 (MMP9) protein.
Host/Isotype: Human/IgG4
Class: Monoclonal
Immunogen: Human MMP9 protein
Production platform: CHO cells
Purification: Affinity chromatography
Storage buffer: PBS, pH 7.2
Storage condition: –20°C
For Research Use Only. Not for use in clinical diagnostics or therapeutics.
Additional information
Antibody Production Scale | 50 ug, 250 ug, 1 mg |
---|---|
Conjugate | None, FITC, HRP, ADC (custom drug) |
You must be logged in to post a review.
Reviews
There are no reviews yet.